Studying the Key Role of Inflammation in Disease Progression and Severity
App Note
The coronavirus (SARS-CoV-2) creates high risk for acute respiratory disease primarily resulting from aggressive inflammation initiated by viral replication in COVID-19 patients.
With radvances in ultra-sensitive Simoa® digital biomarker detection technology, a broad menu of assays are now available to measure baseline levels of immunomodulatory proteins. The sensitivity and precision of the Simoa assay technology enables researchers to measure small changes from baseline levels in both single assay and multiplex panel formats up to 10-analytes per sample.